![](/images/graphics-bg.png)
Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
المؤلفون المشاركون
Park, Yong-Wook
Bang, So-Young
Kang, Young Mo
Choe, Jung-Yoon
Kim, Hyoun-Ah
Lee, Hye-Soon
Yoo, Dae-Hyun
Lee, Chang Keun
Park, Yong-Beom
Kim, Tae-Jong
Suh, Chang-Hee
Bae, Sang-Cheol
Chung, Won Tae
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-12-09
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Objective.
Although two recent randomized placebo-controlled trials of rituximab (RTX) failed to demonstrate efficacy in systemic lupus erythematosus (SLE), clinicians continue to use off-label RTX for cases refractory to current treatments.
We evaluated the effectiveness and safety of rituximab for patients with refractory SLE in Korea.
Methods.
We retrospectively analyzed multicenter patients treated with RTX in Korea.
Results.
39 SLE patients treated with RTX were included in the following manner: lupus nephritis 43.6%, hematologic 33.3%, arthritis 7.8%, myositis 7.8%, and others 7.7%.
All patients had responded poorly to at least one conventional immunosuppressive agent (mean 2.5 ± 1.1, cyclophosphamide 43.6%, mycophenolate mofetil 48.7%, and other drugs) before RTX.
Clinical improvements (complete or partial remission) occurred in patients with renal disease, hematologic disease, arthritis, myositis, and other manifestations at 6 months after RTX.
The SLEDAI score was significantly decreased from 10.8±7.1 at baseline to 6.7±4.0 at 6 months, 6.2±4.1 at 12 months, and 5.5±3.6 at 24 months after RTX (P<0.05).
Among 28 clinical responders, 4 patients experienced a relapse of disease at 25±4 months.
Infections were noted in 3 patients (7.7%).
Conclusion.
RTX could be an effective and relatively safe therapeutic option in patients with severe refractory SLE until novel B-cell depletion therapy is available.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bang, So-Young& Lee, Chang Keun& Kang, Young Mo& Yoo, Dae-Hyun& Bae, Sang-Cheol& Lee, Hye-Soon…[et al.]. 2012. Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-481196
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yoo, Dae-Hyun…[et al.]. Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-481196
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bang, So-Young& Lee, Chang Keun& Kang, Young Mo& Yoo, Dae-Hyun& Bae, Sang-Cheol& Lee, Hye-Soon…[et al.]. Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-481196
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-481196
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)